[go: up one dir, main page]

SV2006002201A - Polimorfo ii de rapamicina y sus utilizaciones ref. am- 101733salvo - Google Patents

Polimorfo ii de rapamicina y sus utilizaciones ref. am- 101733salvo

Info

Publication number
SV2006002201A
SV2006002201A SV2005002201A SV2005002201A SV2006002201A SV 2006002201 A SV2006002201 A SV 2006002201A SV 2005002201 A SV2005002201 A SV 2005002201A SV 2005002201 A SV2005002201 A SV 2005002201A SV 2006002201 A SV2006002201 A SV 2006002201A
Authority
SV
El Salvador
Prior art keywords
rapamycin
rapamycin polymorph
ref
uses ref
poliform
Prior art date
Application number
SV2005002201A
Other languages
English (en)
Inventor
Tianmin Zhu
Mahdi B Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35431373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2006002201(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2006002201A publication Critical patent/SV2006002201A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

PROVEE FORMA POLIFORMA II DE RAPAMICINA. ESTA INVENCION TAMBIEN PROVEE PROCESOS PARA PREPARAR FORMA POLIFORMA II DE RAPAMICINA Y COMPOSICIONES FARMACEUTICAS QUE INCLUYEN FORMA POLIFORMA II DE RAPAMICINA.
SV2005002201A 2004-08-20 2005-08-18 Polimorfo ii de rapamicina y sus utilizaciones ref. am- 101733salvo SV2006002201A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60309604P 2004-08-20 2004-08-20

Publications (1)

Publication Number Publication Date
SV2006002201A true SV2006002201A (es) 2006-05-09

Family

ID=35431373

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002201A SV2006002201A (es) 2004-08-20 2005-08-18 Polimorfo ii de rapamicina y sus utilizaciones ref. am- 101733salvo

Country Status (22)

Country Link
US (1) US7282505B2 (es)
EP (1) EP1781671A1 (es)
JP (1) JP2008510710A (es)
KR (1) KR20070051863A (es)
CN (1) CN101039948A (es)
AR (1) AR050374A1 (es)
AU (1) AU2005277407A1 (es)
BR (1) BRPI0514407A (es)
CA (1) CA2575887A1 (es)
CR (1) CR8929A (es)
EC (1) ECSP077268A (es)
GT (1) GT200500223A (es)
IL (1) IL181170A0 (es)
MX (1) MX2007002044A (es)
NO (1) NO20071050L (es)
PA (1) PA8642501A1 (es)
PE (1) PE20060649A1 (es)
RU (1) RU2007104518A (es)
SV (1) SV2006002201A (es)
TW (1) TW200608973A (es)
WO (1) WO2006023627A1 (es)
ZA (1) ZA200701453B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101131794B1 (ko) 2002-07-30 2012-03-30 와이어쓰 엘엘씨 Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
NZ574654A (en) * 2006-07-25 2012-03-30 Abbott Lab Crystalline forms of rapamycin analogs
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US8414526B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20080276935A1 (en) * 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20080175887A1 (en) * 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US20110275798A1 (en) * 2009-01-21 2011-11-10 Rakesh Bhaiyyaram Mendhe Method for Determination of Sirolimus Stability and Process for Preparing Its Stable Form
US20120231037A1 (en) 2009-02-02 2012-09-13 Yissum Research Development Companyof the Hebrew U Crystalline drug-containing coatings
US20120252834A1 (en) * 2009-08-05 2012-10-04 The Government Of United States, As Represented By The Secretary Of The Army Novel use and method of rapamycin to treat toxic shock
WO2015103447A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
AU2012338869A1 (en) 2011-11-15 2014-06-05 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the Janus Kinase 2-Signal Transducer and Activator of Transcription 5 pathway
EP2869818A1 (en) 2012-07-06 2015-05-13 Novartis AG Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
DK2968281T3 (da) 2013-03-13 2020-11-02 Univ Texas Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
EP3738592B1 (en) 2013-10-08 2022-01-26 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
JP2017505789A (ja) * 2014-02-11 2017-02-23 ラム・セラピューティクス，インコーポレーテッド リンパ脈管筋腫症の治療のためのラパマイシン
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
BR112016022598A8 (pt) 2014-04-04 2021-06-29 Ai Therapeutics Inc composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
CN106478663A (zh) * 2015-08-26 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种依维莫司的干燥方法
ES2871499T3 (es) 2017-05-15 2021-10-29 Bard Inc C R Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物
WO2020101675A1 (en) 2018-11-14 2020-05-22 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
WO2020209828A1 (en) 2019-04-08 2020-10-15 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
UA41884C2 (uk) 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів

Also Published As

Publication number Publication date
ECSP077268A (es) 2007-03-29
MX2007002044A (es) 2007-03-29
PA8642501A1 (es) 2006-05-16
US7282505B2 (en) 2007-10-16
KR20070051863A (ko) 2007-05-18
NO20071050L (no) 2007-05-15
ZA200701453B (en) 2010-08-25
GT200500223A (es) 2006-03-09
US20060040971A1 (en) 2006-02-23
EP1781671A1 (en) 2007-05-09
IL181170A0 (en) 2007-07-04
CA2575887A1 (en) 2006-03-02
AU2005277407A1 (en) 2006-03-02
AR050374A1 (es) 2006-10-18
BRPI0514407A (pt) 2008-06-10
WO2006023627A1 (en) 2006-03-02
WO2006023627A8 (en) 2006-11-30
CR8929A (es) 2007-08-28
RU2007104518A (ru) 2008-09-27
TW200608973A (en) 2006-03-16
PE20060649A1 (es) 2006-08-10
JP2008510710A (ja) 2008-04-10
CN101039948A (zh) 2007-09-19

Similar Documents

Publication Publication Date Title
SV2006002201A (es) Polimorfo ii de rapamicina y sus utilizaciones ref. am- 101733salvo
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
AR059978A1 (es) Composiciones farmaceuticas
GT200900027A (es) Compuestos organicos
PA8693101A1 (es) Compuestos de isoindol-imida y composiciones que los incluyen y mètodos para su uso
HN2008001191A (es) Compuestos de biciclolactama sustituida
ZA200901224B (en) New small molecule inhibitors of MDM2 the uses thereof
GT200900010A (es) Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
CR10186A (es) Inhibidores de 11-beta-hsd1
JO2778B1 (en) Certain Compounds, Compositions and Methods
CR10026A (es) Formulación de profármacos para el vhc
HN2007006799A (es) Analogos de biaril piperazinil-piridina sustituidos
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
NO20084334L (no) Farmasoytiske sammensetninger
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI0818804A2 (pt) Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
DK1931315T3 (da) Depotformuleringer af nalbufin
UY30748A1 (es) Compuesto0s novedosos
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
HN2007000437A (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
SV2009003002A (es) Procesos para la sintesis convergente de los derivados de caliqueamicina
PA8618901A1 (es) Biaril sulfonamidas y metodo para el uso de las mismas
PA8667201A1 (es) Nuevos compuestos farmaceuticos
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
CR9257A (es) Polimorfo cci-779 y uso del mismo